{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-264057","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.987593+00:00","generated_at":"2026-06-09T08:37:23.651812+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Quince Therapeutics appoints Brendan Hannah as COO, effective Oct 24, 2023","bullets":["Brendan Hannah, age 38, appointed COO; continues as Chief Business Officer and principal financial/accounting officer.","Granted option to purchase 75,000 shares at $0.99, vesting over 48 months from Oct 23, 2023.","Served as Chief Business Officer since May 2022; previously COO of Novosteo Inc.","No family relationships or transactions requiring disclosure under Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-264057","json":"https://secwatch.observer/filing/0001193125-23-264057.json","markdown":"https://secwatch.observer/filing/0001193125-23-264057.md","text":"https://secwatch.observer/filing/0001193125-23-264057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523264057/0001193125-23-264057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523264057/d563197d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:37:23.651812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5cb1eff697","claim":"Brendan Hannah was appointed as Chief Operating Officer at Quince Therapeutics, Inc..","evidence_excerpt":"On October 24, 2023, the Board of Directors of Quince Therapeutics, Inc. (the “Company”) appointed Brendan Hannah to the position of Chief Operating Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523264057/0001193125-23-264057-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}